Advanced Cellular Dynamics

Pre-clinical

Seattle, United StatesFounded 2013acd.bio

Advanced Cellular Dynamics is pioneering a new class of engineered cellular therapeutics focused on immune modulation and targeted cancer treatment. The company's core technology enables precise control over cell fate and function, aiming to create more persistent and potent therapies. With a pipeline advancing through early clinical development, ACD is positioned at the forefront of the next wave of cell therapy innovation. The company is backed by leading life science investors and maintains strategic research collaborations with academic institutions.

Founded

2013

Employees

50-100

Focus

Cell TherapyRegenerative Medicine

AI Company Overview

Technology Platform

Proprietary Modular Cellular Reprogramming (MCR) Platform that uses epigenetic editing and synthetic biology to create engineered cell therapies with enhanced persistence, specificity, and durability.

Funding History

Total raised: $21M

Seed$3.5MUndisclosedMay 15, 2022

Series A$15MUndisclosedSep 15, 2017

Seed$2.5MUndisclosedJun 15, 2015

Opportunities

Significant opportunity in improving upon existing cell therapies for relapsed cancer patients and pioneering cell therapy in large autoimmune disease markets like Crohn's.

The platform technology also presents licensing potential to larger pharmaceutical partners.

Risk Factors

High clinical risk associated with a novel epigenetic reprogramming platform.

Faces intense competition from established cell therapy companies and alternative modalities.

Manufacturing complexity and future financing needs present additional challenges.

Competitive Landscape

Competes with major commercial CAR-T developers (Gilead, Novartis, BMS) and clinical-stage biotechs in next-gen cell therapy. Differentiation hinges on proving its epigenetic reprogramming leads to superior persistence and efficacy in head-to-head comparisons.